The clinically proven formula pairs NAD+ with its precursors to replenish skin cells and address nine signs of skin aging for healthier, more resilient-looking skin NEW YORK, March 24, 2026 (GLOBE NEWSWIRE) -- Obagi Medical (“Obagi”), a leader in advanced skincare innovation, the originator of medical-grade skincare and part of Waldencast plc (NASDAQ: WALD) (“Waldencast” or the “Company”), is proud to announce the latest innovation in advanced skin science and longevity with the launch of its newest breakth ...

Core Insights - Obagi Medical collaborates with ProMD Health for the ALOHA Program to evaluate MagIQ and integrated skincare protocols across multiple states [1][2] - ProMD Health's network consists of 17 practices, emphasizing clinical excellence and real-world evaluation [1][5] - The ALOHA Program aims to enhance patient satisfaction and ensure high-quality results through standardized data collection [5][6] Company Overview - Obagi Medical is a leading innovator in physician-dispensed skincare with over 35 years of experience, focusing on various skin concerns [8] - ProMD Health operates as a physician-led multi-state practice network with a commitment to a People First approach [9] - Waldencast plc, the parent company of Obagi, aims to build a global beauty and wellness platform through purpose-driven brands [11] Program Details - The ALOHA Program combines clinical education from Obagi with hands-on experience from ProMD Health injectors [2] - The program evaluates both clinical efficacy and patient experience, contributing to real-world evidence supporting MagIQ's performance [5][6] - MagIQ utilizes proprietary MACRO Core Technology for stable hyaluronic acid delivery, aiming for natural-looking results [6]

Core Insights - Waldencast reported FY 2025 net revenue of $272.1 million, flat compared to FY 2024, with an Adjusted EBITDA of $16.1 million, reflecting a significant decline of 60.1% year-over-year [1][22][19] - The company experienced mixed results across its portfolio in Q4 2025, with net revenue of $72.0 million, also flat compared to Q4 2024, and an Adjusted EBITDA of $6.6 million, down 41.4% year-over-year [1][11][13] - Obagi Medical showed revenue acceleration due to transformation efforts and brand momentum, while Milk Makeup maintained U.S. consumption growth despite international market softness [1][2][5] Financial Performance - For Q4 2025, Waldencast's net revenue decreased by 0.1% year-over-year to $72.0 million, with a gross profit of $48.2 million and an Adjusted Gross Profit of $51.2 million, representing a gross margin of 71.2% [11][12][14] - The net loss for Q4 2025 was $33.5 million, primarily due to financing costs related to credit facility refinancing [12][31] - For the year ended 2025, net revenue decreased by 0.7% to $272.1 million, with a gross profit of $183.0 million and an Adjusted Gross Profit margin of 71.6% [16][17][22] Brand Performance - Obagi Medical achieved a net revenue of $161.6 million in FY 2025, an increase of 8.3% from FY 2024, driven by strong international demand and U.S. direct-to-consumer success [22][15] - Milk Makeup's net revenue for FY 2025 was $110.4 million, down 11.4% year-over-year, impacted by softer international consumption despite a 6.2% growth in U.S. consumption [22][6][5] Strategic Initiatives - Waldencast advanced its strategic priorities in 2025 by entering the medical aesthetics market and enhancing financial flexibility through the sale of the Obagi Japan trademark for $82.5 million [1][8] - The company is focusing on strengthening its balance sheet and strategic focus, with a comprehensive review of strategic alternatives underway [7][8] - Obagi Medical's upcoming launch of Obagi saypha MagIQ injectables in Q1 2026 is expected to double its addressable market and solidify its leadership in integrated skincare and medical aesthetics [2][3] Liquidity and Debt Management - As of December 31, 2025, Waldencast held $30.4 million in cash and cash equivalents, with net debt totaling $121.7 million, a reduction from $154.2 million in the previous year [20][21] - The company entered into a new $225 million three-year credit facility in November 2025, utilizing proceeds from the sale of the Obagi Japan trademark to reduce debt [20][8]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR o SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FORM 20-F (Mark One) o REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934: For the fiscal year ended December 31, ...

Core Viewpoint - Waldencast plc is set to release its Fourth Quarter and Fiscal Year 2025 earnings on March 13, 2026, prior to the U.S. market opening, without hosting a conference call due to an ongoing strategic review [1]. Company Overview - Waldencast plc aims to establish a global best-in-class beauty and wellness operating platform by developing, acquiring, and scaling purpose-driven brands [2]. - The company’s brand-led business model focuses on customer proximity, business agility, and market responsiveness while preserving each brand's unique identity [2]. - The initial step towards this vision was the business combination with Obagi Medical and Milk Makeup, which allows its brands to leverage operational scale and expertise in managing global beauty brands [2]. - Waldencast's platform offers a balanced portfolio to mitigate category fluctuations, asset-light efficiency, and the agility of entrepreneurial indie brands [2].

Core Insights - Obagi Medical has selected Schweiger Dermatology as a key partner for its Aesthetics Leadership with the Hyaluronic Acid (ALOHA) Program, emphasizing clinical excellence and rapid access to care [1] Company Overview - Obagi Medical is recognized as a leading innovator in physician-dispensed skincare and aesthetic solutions, with over 35 years of experience in the industry [7] - Schweiger Dermatology is a prominent national dermatology practice that offers a range of services including medical, cosmetic, and surgical dermatology, focusing on high-quality, personalized care [8] - Waldencast plc, the parent company of Obagi Medical, aims to build a global beauty and wellness platform by developing and scaling purpose-driven brands [9] Partnership Details - The partnership will generate real-world data to translate clinical safety and efficacy from FDA pivotal trials into everyday practice [2] - The ALOHA Program includes a Phase 4 clinical study and a real-world evaluation program to enhance patient satisfaction and provider-patient relationships [3] - Initial program activities are expected to commence in early 2026, with findings to be presented at internal leadership meetings and key industry conferences [4] Product Information - Obagi saypha MagIQ™, developed by Croma-Pharma GmbH, utilizes proprietary MACRO Core Technology to create a stable hyaluronic acid matrix, aiming for natural-looking results and high performance [5]

Core Insights - Obagi Medical has selected It's a Secret Med Spa as a premier luxury partner for its ALOHA Program, focusing on translating clinical safety and efficacy into real-world applications [1][3] - The partnership aims to enhance patient satisfaction and strengthen provider-client relationships through hands-on experience with Obagi's saypha MagIQ™ and structured evaluation processes [2][3] Company Overview - Obagi Medical is a leading innovator in physician-dispensed skincare with over 35 years of experience, known for addressing various skin concerns and recognized as the fastest-growing professional skincare brand in the U.S. in 2024 [5][9] - It's a Secret Med Spa specializes in advanced aesthetic treatments, being the largest provider of neurotoxins and dermal fillers in Texas and the Southwestern U.S., with 15 high-end locations [6][9] - Waldencast plc, the parent company of Obagi Medical, aims to build a global beauty and wellness platform by developing and scaling purpose-driven brands [8]

Core Insights - Aesthetic Record has been selected as a key partner for Obagi Medical's ALOHA Program, focusing on the integration of technology and real-world data to enhance aesthetic practices across the U.S. [1][4] Company Overview - Obagi Medical is recognized as a leading innovator in physician-dispensed skincare, with over 35 years of experience and a focus on addressing various skin concerns [6]. - Aesthetic Record is the leading Electronic Medical Records (EMR) and Practice Management platform specifically designed for the medical aesthetics industry, serving thousands of practices [7][8]. Partnership Details - The partnership aims to leverage Aesthetic Record's technology to capture real-world data, enhancing the launch of Obagi's new injectable, saypha MagIQ™ [2][4]. - The ALOHA Real-World Program will provide Aesthetic Record users with hands-on experience with Obagi products, aiming to improve patient satisfaction and provider relationships [2][3]. Technology and Innovation - Obagi's saypha MagIQ™ utilizes proprietary MACRO Core Technology to create a stable hyaluronic acid matrix, designed for natural-looking results and high performance [4]. - Aesthetic Record's platform offers integrated tools for efficient charting, compliance monitoring, and performance tracking, which are essential for high-volume aesthetic practices [2][8]. Industry Impact - Initial findings from the partnership will be presented at the Aesthetic Next conference, showcasing the benefits of the new protocols and products within the Aesthetic Record ecosystem [3]. - The collaboration is positioned to advance the aesthetics industry by combining innovative injectables with streamlined technology, ultimately aiming for better patient outcomes [2].

Core Insights - Waldencast PLC (NASDAQ: WALD) has received an average recommendation of "Moderate Buy" from six ratings firms, with one sell, one hold, and four buy recommendations. The average twelve-month price target is $4.4167 [2] Analyst Recommendations - Weiss Ratings reiterated a "sell (e+)" rating on Waldencast shares [3] - Jefferies Financial Group initiated coverage with a "buy" rating and a price target of $2.00 [3] - Canaccord Genuity Group lowered its price target from $5.00 to $4.00 while maintaining a "buy" rating [3] - Telsey Advisory Group downgraded the stock from "outperform" to "market perform" with a price objective of $3.00 [3] Institutional Holdings - UBS Group AG increased its holdings by 466.2% in Q3, owning 838,536 shares valued at $1.66 million after purchasing 690,441 shares [4][5] - Milestones Administradora de Recursos Ltda. raised its stake by 10.3% in Q3, owning 2,425,677 shares valued at $4.803 million after buying 225,677 shares [4][5] - Geode Capital Management LLC increased its holdings by 62.2% in Q2, owning 586,566 shares worth $1.437 million after purchasing 224,905 shares [4][5] - McAdam LLC raised its holdings by 174.6% in Q3, owning 63,014 shares worth $125,000 after buying 40,063 shares [4][5] - Squarepoint Ops LLC acquired a new position worth $78,000 in Q3 [4][5] - Institutional investors and hedge funds currently own 41.97% of the stock [4][5] Price Performance - Waldencast shares opened at $1.80, with a twelve-month low of $1.45 and a high of $3.54 [6] - The company has a current ratio of 1.53, a quick ratio of 0.67, and a debt-to-equity ratio of 0.32 [6] - The 50-day simple moving average is $1.80, and the 200-day simple moving average is $1.88 [6] Financial Performance - Waldencast reported an EPS of ($0.69) for the last quarter, with revenue of $66.14 million [7] - Analysts expect the company to post an EPS of -0.14 for the current year [7] Company Overview - Waldencast operates in the beauty and wellness sector, focusing on developing, acquiring, and scaling various brands [8] - The company offers products under the Obagi Medical, Obagi Clinical, and Obagi Professional brands, as well as clean makeup products under the Milk Makeup brand [8][9] - Its products are sold to dermatologists, plastic surgeons, and other physicians, as well as through direct sales and distribution partners [9]

Core Insights - DermFx has been selected as a key partner for Obagi Medical's ALOHA Program, focusing on real-world data generation to validate the clinical safety and efficacy of Obagi's Hyaluronic Acid products in everyday practice [1][2] Company Overview - Obagi Medical is a leading innovator in physician-dispensed skincare with over 35 years of experience, known for addressing various skin concerns and recognized as the fastest-growing professional skincare brand in the U.S. in 2024 [5] - DermFx is a top-ranked medical spa in Southern California, specializing in advanced aesthetic treatments and has served tens of thousands of patients over 20+ years, emphasizing exceptional patient care and personalized protocols [6][7] - Waldencast plc, the parent company of Obagi Medical, aims to build a global beauty and wellness platform by developing and scaling purpose-driven brands [8] Partnership Details - The partnership aims to provide DermFx with access to cutting-edge protocols and real-world insights, enhancing patient outcomes and allowing independent med spas to compete effectively [2][3] - The ALOHA Real-World Program will offer DermFx providers hands-on experience with Obagi saypha MagIQ™, utilizing proprietary technology for improved aesthetic results [3] Program Objectives - The ALOHA Program is designed to drive patient satisfaction and strengthen relationships between patients and DermFx providers through structured evaluations and standardized data capture [2] - Initial findings from the program will be presented at internal team meetings and regional events to highlight the benefits of the new protocols and products [2]